Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 26, 2022CJC OpenOpen Access

Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review

View Full Paper
Ask AI
Bookmark
Share

Key result

Standard pharmacologic therapies for HFrEF require careful dosing and monitoring of renal function and potassium in patients with concurrent chronic kidney disease.

Why the study?

Concurrent chronic kidney disease in patients with HFrEF challenges the initiation and titration of the four standard pharmacologic therapies.

Population

Patients with HFrEF and concurrent CKD

Design

Contemporary review and case-based approach

Authors

ABArden R. BarryGeneral / Preventive / Lipids

Discussion

Loading...

Member takes

Implication

May warrant enhanced monitoring with HFrEF therapies in CKD; leaves open optimal protocols for prospective trials.

Structured PICO

P
Population
Patients with heart failure with reduced ejection fraction (HFrEF) and concurrent chronic kidney disease (CKD)
I
Intervention
Standard pharmacologic therapies for HFrEF (renin-angiotensin system inhibitors, sacubitril/valsartan, beta-blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists)

This review provides practical guidance on initiating and titrating the four pillars of HFrEF therapy in patients with concurrent chronic kidney disease, emphasizing careful monitoring of renal function and electrolytes.

Cite This Study

Arden R. Barry (2022) conducted a review in Heart failure with reduced ejection fraction and chronic kidney disease. Pharmacologic therapies for HFrEF was evaluated. Standard pharmacologic therapies for HFrEF require careful dosing and monitoring of renal function and potassium in patients with concurrent chronic kidney disease.

synapsesocial.com/papers/6a6b79d63e46b6df0af30e57https://doi.org/10.1016/j.cjco.2022.06.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function2013 · 248 citations
  2. 2Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure2012 · 272 citations
  3. 3Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors2015 · 161 citations
  4. 4Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure2014 · 6,985 citations
  5. 5Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial2021 · 45 citations